Eribulin
- Generic Name
- Eribulin
- Brand Names
- Halaven, Eribulin Baxter, Mevlyq
- Drug Type
- Small Molecule
- Chemical Formula
- C40H59NO11
- CAS Number
- 253128-41-5
- Unique Ingredient Identifier
- LR24G6354G
- Background
Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors .
- Indication
For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer.
- Associated Conditions
- Metastatic Liposarcoma, Refractory, metastatic Breast cancer, Unresectable Liposarcoma
An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory
- Conditions
- Metastatic Breast Cancer
- First Posted Date
- 2010-11-15
- Last Posted Date
- 2015-05-22
- Lead Sponsor
- Eisai Inc.
- Registration Number
- NCT01240421
Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies
- First Posted Date
- 2010-06-11
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT01142661
Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2010-05-20
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 98
- Registration Number
- NCT01126736
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
- First Posted Date
- 2010-05-20
- Last Posted Date
- 2022-02-28
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 92
- Registration Number
- NCT01126749
QT Interval Prolongation Study of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors
- First Posted Date
- 2010-04-19
- Last Posted Date
- 2012-04-13
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 26
- Registration Number
- NCT01106248
- Locations
- 🇫🇷
Medicale, Dunkerque, *CS, France
🇫🇷Service d'Oncologie, Dunkerque, *CS, France
Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2010-04-15
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 123
- Registration Number
- NCT01104155
Evaluating the Pharmacokinetics and Tolerance of Co-administration of Oral Multiple Dose of Ketoconazole and an IV (Bolus) Infusion of Eribulin in Patients With Advanced Solid Tumors
- First Posted Date
- 2009-10-23
- Last Posted Date
- 2013-09-23
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 12
- Registration Number
- NCT01000376
- Locations
- 🇳🇱
The Netherlands Cancer Institute, Amsterdam, Noord-Holland, Netherlands
Study of E7389 for Advanced or Metastatic Breast Cancer
- First Posted Date
- 2009-08-25
- Last Posted Date
- 2013-08-15
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 81
- Registration Number
- NCT00965523
A Study to Determine the Metabolism and Elimination of Carbon-14 Labeled Eribulin Acetate (14C-Eribulin) in Patients With Advanced Solid Tumors
- First Posted Date
- 2009-05-27
- Last Posted Date
- 2012-03-09
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT00908908
- Locations
- 🇳🇱
Netherlands Cancer Institute, Amsterdam, Netherlands
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer
- First Posted Date
- 2009-04-09
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT00879086
- Locations
- 🇺🇸
Northwest Cancer Center, Corpus Christi, Texas, United States
🇺🇸Texas Oncology-Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Northern Utah Associates, Ogden, Utah, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.